Results 131 to 140 of about 2,156 (171)

Broad‐spectrum matrix metalloproteinase inhibitor marimastat–induced musculoskeletal side effects in rats

Arthritis & Rheumatism, 2003
AbstractObjectiveTo characterize the clinical and histopathologic changes in a rat model of broad‐spectrum matrix metalloproteinase (MMP)–induced musculoskeletal syndrome (MSS), and to facilitate research into the causes and treatments of MSS in humans.MethodsMale Lewis rats weighing 150–180 gm were administered 10–30 mg of the broad‐spectrum MMP ...
Richard, Renkiewicz, Luping, Qiu, Charles, Lesch, Xin, Sun, Radhika, Devalaraja, Theresa, Cody, Eric, Kaldjian, Howard, Welgus, Vijaykumar, Baragi   +8 more
openaire   +3 more sources

The effect of marimastat, a metalloprotease inhibitor, on allergen-induced asthmatic hyper-reactivity

Toxicology and Applied Pharmacology, 2004
This pilot study was designed to assess whether a synthetic matrix metalloproteinase (MMP) inhibitor has anti-inflammatory properties in mild asthma. Tumor necrosis factor alpha (TNFalpha) has been shown to be an important cytokine in the pathogenesis of allergic airway inflammatory responses, and its release can be inhibited by MMP inhibitors.
C.Allen Bruce, Peter Thomas
openalex   +3 more sources

An improved synthesis of the broad spectrum matrix metalloprotease inhibitor marimastat

Tetrahedron Letters, 2000
Abstract A considerably shortened synthesis of the broad spectrum matrix metalloproteinase (MMP) inhibitor marimastat has been achieved by a direct hydroxylamino ring opening of a key acetonide intermediate.
Richard Davenport, Robert J. Watson
openalex   +2 more sources

The interaction of metal ions and Marimastat with matrix metalloproteinase 9

Journal of Inorganic Biochemistry, 2003
The effect of a range of metal ions on the ability of Marimastat to inhibit matrix metalloproteinase 9 (MMP-9) was examined in a fluorescence based proteolytic assay. Whilst none of the metals examined significantly affected the inhibitory ability of Marimastat, several metal ions did have a significant effect on MMP-9 activity itself.
Underwood, C. K., Min, D., Lyons, J. G., Hambley, T. W.   +3 more
openaire   +4 more sources

Marimastat

, 2006

  +5 more sources

The Matrix Metalloproteinase Inhibitor Marimastat Promotes Neural Progenitor Cell Differentiation into Neurons by Gelatinase-Independent TIMP-2-Dependent Mechanisms

Stem Cells and Development, 2012
Maddalena Sinno, Stefano Biagioni, Maria Antonietta Ajmone‐Cat, Irene Pafumi, Pasquale Caramanica, Virginia Medda, Gaetana A. Tonti, Luisa Minghetti, Ferdinando Mannello, Emanuele Cacci   +9 more
openalex   +2 more sources

Tumour marker levels during marimastat therapy

The Lancet, 1996
Martin Gore, Roger A’Hern, Monika Stankiewicz, M L Slevin   +3 more
  +4 more sources

Regional intravenous limb perfusion compared to systemic intravenous administration for marimastat delivery to equine lamellar tissue

Journal of Veterinary Pharmacology and Therapeutics, 2015
Charlie J. Underwood, Simon Collins, Paul C. Mills, Andrew W. van Eps, Rachel Allavena, Carlos E. Medina‐Torres, C. C. Pollitt   +6 more
openalex   +2 more sources

Is British Biotech's Marimastat a major cancer drug?

Nature Biotechnology, 1996
Sylvia Davidson
openalex   +2 more sources

Phase I Trial of the Matrix Metalloproteinase Inhibitor Marimastat Combined with Carboplatin and Paclitaxel in Patients with Advanced Non–Small Cell Lung Cancer

Clinical Cancer Research, 2005
John R. Goffin, Ian C. Anderson, Jeffrey G. Supko, Joseph P. Eder, Geoffrey I. Shapiro, Thomas J. Lynch, Margaret A. Shipp, Bruce E. Johnson, Arthur T. Skarin   +8 more
openalex   +2 more sources